Oct 9, 2017 · 55m · capital-allocators
Jason Klein – Investing to Cure Cancer (Capital Allocators, EP.28)
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
Ted Seides interviews Jason Klein, Chief Investment Officer at Memorial Sloan Kettering Cancer Center, exploring how MSK constructs its $4.5 billion multi-asset portfolio, evaluates exceptional manager talent, and aligns institutional investing with the hospital's mission to cure cancer.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. Ted holds 27.4% of the talking time here. How this is scored →
speaking balance: gold is Ted, purple is the guest (3 minute bins)
In an overall exceptionally polite and collaborative discussion, Jason gently counters Ted's suggestion that premortems should precede commitment by explaining why maintaining psychological commitment is essential to the premortem exercise.
Hardest push from Ted ▶ 18:23 Ted challenges 100 bps illiquidity quantificationTed directly challenges Jason's 100 basis point annual illiquidity premium rule of thumb, questioning how one can cleanly isolate that delta when comparing a public tech picker to early-stage venture capital.
Biggest teaching moment ▶ 41:30 Jason explains the STAGE framework breakdownJason educates Ted on why traditional asset classes broke down during the GFC and explains MSK's proprietary STAGE framework for slicing underlying risk drivers rather than relying on standard labels.
Ted holds their own ▶ 21:21 Ted points out missing entry valuation parameterTed actively steps in to point out that Jason's structural framework left out entry valuation, forcing Jason to incorporate entry price into his three-legged stool paradigm.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | Ted as informed peer | Guest teaching | Guest disagreement | Ted pushing back | Why |
|---|---|---|---|---|---|---|
| Connecting Investments to MSK's Mission Through 'Memorial Moments' | 4 | 3 | 0 | 1 | Ted opens with a personal connection to MSK via Cycle for Survival and prompts Jason to describe their weekly Memorial Moments. Ted makes a light observation about a cancer center operating like a competitive business, which Jason cordially affirms. | |
| Building a Multi-Asset Class Toolkit from Bottom-Up Private Equity Skills | 5 | 4 | 0 | 1 | Ted asks how bottom-up private equity skills translate into multi-asset allocation. Jason explains his progression at MoMA and MSK, outlining his core beliefs about research in quirky niches and aligning with a single client's risk appetite. | |
| MSK Asset Allocation Targets and the Illiquidity Premium Framework | 5 | 5 | 0 | 1 | Ted asks Jason to break down the asset allocation percentages and compare illiquid versus liquid investments. Jason outlines his portfolio targets and explains his rule-of-thumb heuristic requiring a 100 basis points illiquidity premium per year. | |
| Evaluating Illiquidity Premiums, Structural Terms, and Research Engines | 6 | 4 | 0 | 2 | Ted pushes on how to practically quantify a 100 basis point premium across public vs venture managers. Jason explains the concrete structural terms (fee breaks, carry crystallization) and the qualitative aspects of a manager's research engine. | |
| Manager Selection: The Three-Legged Barstool and Entry Valuations | 6 | 4 | 0 | 2 | Ted notices that entry valuation was missing from Jason's initial list and inserts it into the discussion. Jason agrees, explaining his three-legged barstool framework (philosophy, strategy, process) and how market entry valuations fit into the surrounding environment. | |
| Differentiating Manager Character: Internal Competitiveness and Self-Learning | 4 | 4 | 0 | 0 | Ted asks for specific character traits that separate selected managers from rejected ones. Jason highlights internal competitiveness, continuous self-learning, and intellectual curiosity through concrete examples. | |
| Sponsor Message: Ridgeline | 1 | 1 | 0 | 0 | Ted delivers an ad break for Ridgeline before circling back to discuss intellectual curiosity and productivity in managers. | |
| Flexible Mandate Managers vs. Niche Opportunity Sizing | 5 | 4 | 0 | 1 | Ted inquires about manager turnover and sourcing pipelines. Jason contrasts long-term flexible mandate managers (FMMs) with short-term niche opportunities, summarizing their strategy as an iterative two-step game plan. | |
| Due Diligence Mechanics: Qualitative Corroboration and the '30 Questions' | 5 | 5 | 0 | 0 | Ted asks about the due diligence workflow behind the scenes. Jason walks through off-list referencing, quantitative track record decomposition, and MSK's team-wide '30 questions' review. | |
| Storyboarding and Conducting Post-Commitment Premortem Analysis | 6 | 5 | 0 | 2 | Ted probes on the timing of post-commitment premortems and whether conducting them post-funding makes allocators biased. Jason acknowledges the tension and explains how the exercise provides a forward-looking monitoring checklist. | |
| Leveraging the Investment Committee Efficiently and Respectfully | 5 | 4 | 0 | 1 | Ted asks how MSK engages its high-profile investment committee without wasting their time on small manager allocations. Jason explains using advance strategy dashboards and pre-meeting materials to keep committee discussions focused on high-level risk. | |
| Bottom-Up Implementation and the Five-Lane Highway Analogy | 6 | 5 | 0 | 2 | Ted and Jason discuss the viability of conventional asset allocation buckets in a low-yield environment. Jason introduces the STAGE framework and his five-lane highway analogy, explaining how bottom-up implementation interacts with top-down risk limits. | |
| Macro Environment Concerns: Mispricing of Capital and High Multiples | 4 | 4 | 0 | 1 | Ted asks what worries Jason most about current capital markets. Jason cites the mispricing of capital driven by artificially low interest rates pushing valuation metrics into top deciles. |